Willner & Heller’s Bristol-Myers Squibb BMY Stock Holding History

Willner & Heller’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,131	Closed	-$255K	–	155
2024 Q2	$255K	Sell	6,131 -2,912	-32%	-$130K	0.24%	127
2024 Q1	$490K	Buy	9,043 +3,025	+50%	+$154K	0.49%	70
2023 Q4	$309K	Buy	+6,018	New	+$316K	0.34%	101

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Willner & Heller's BMY Position: Q3 2024 in Review

Willner & Heller sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 6,131 shares — an estimated $255K sold.

Willner & Heller first reported a position in BMY in Q4 2023 and held it in 3 quarters. The position peaked at $490K in Q1 2024. 2,263 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Willner & Heller reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Willner & Heller sold 6,131 Bristol-Myers Squibb shares in Q3 2024, an estimated $255K.
Willner & Heller first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 3 quarters.
Willner & Heller's Bristol-Myers Squibb position peaked at $490K in Q1 2024.
2,263 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Willner & Heller's 13F filing for Q3 2024, filed 10 Oct 2024.